DK2047253T3 - Elektrokemisk påvisning af magnetisk partikelmobilitet - Google Patents
Elektrokemisk påvisning af magnetisk partikelmobilitet Download PDFInfo
- Publication number
- DK2047253T3 DK2047253T3 DK07766626.1T DK07766626T DK2047253T3 DK 2047253 T3 DK2047253 T3 DK 2047253T3 DK 07766626 T DK07766626 T DK 07766626T DK 2047253 T3 DK2047253 T3 DK 2047253T3
- Authority
- DK
- Denmark
- Prior art keywords
- fluid
- electrodes
- coagulation
- particles
- exemplary embodiment
- Prior art date
Links
- 239000006249 magnetic particle Substances 0.000 title claims description 16
- 238000000835 electrochemical detection Methods 0.000 title description 3
- 239000002245 particle Substances 0.000 claims description 53
- 239000012530 fluid Substances 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 44
- 238000012544 monitoring process Methods 0.000 claims description 39
- 230000015271 coagulation Effects 0.000 claims description 25
- 238000005345 coagulation Methods 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 23
- 241000894007 species Species 0.000 claims description 21
- 230000008859 change Effects 0.000 claims description 20
- 230000005291 magnetic effect Effects 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 10
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 10
- 239000003114 blood coagulation factor Substances 0.000 claims description 10
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical class [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 claims description 10
- 238000004082 amperometric method Methods 0.000 claims description 6
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 4
- 108010000499 Thromboplastin Proteins 0.000 claims description 4
- 102000002262 Thromboplastin Human genes 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 3
- 239000012491 analyte Substances 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 239000003998 snake venom Substances 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000010292 electrical insulation Methods 0.000 claims 1
- 238000012806 monitoring device Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 238000009792 diffusion process Methods 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 8
- 229960005080 warfarin Drugs 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 230000005298 paramagnetic effect Effects 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000005518 electrochemistry Effects 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- DLURHXYXQYMPLT-UHFFFAOYSA-N 2-nitro-p-toluidine Chemical compound CC1=CC=C(N)C([N+]([O-])=O)=C1 DLURHXYXQYMPLT-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- -1 etc.) Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4905—Determining clotting time of blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/403—Cells and electrode assemblies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
- G01N2011/006—Determining flow properties indirectly by measuring other parameters of the system
- G01N2011/0086—Determining flow properties indirectly by measuring other parameters of the system magnetic properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
- G01N11/10—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material
- G01N11/14—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane
- G01N2011/147—Magnetic coupling
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1027—Determining speed or velocity of a particle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
Claims (21)
1. Fremgangsmåde til elektrokemisk monitorering af mobiliteten for partikler i et fluid som reaktion på et eksternt felt, hvilken fremgangsmåde omfatter: tilvejebringelse af fluid i en elektrokemisk celle, hvilket fluid omfatter en prøve og partikler, der kan bevæges under påvirkning af det eksterne felt, hvor partiklerne er magnetiske; påføring af et eksternt felt, hvor det eksterne feltomfatter et ændrende eksternt magnetfelt; monitorering af en elektrisk egenskab for fluidet; observering af den elektriske egenskab forårsaget af partikelbevægelse induceret af det eksterne felt, hvor omfanget af den elektriske egenskab kan ændres på grund af en ændring i partiklernes mobilitet; og påvisning af en ændring i fluidets fysiske tilstand eller i partiklernes mobilitet ud fra en ændring i omfanget af den observerede elektriske egenskab.
2. Fremgangsmåde ifølge krav 1, hvor fluidet endvidere omfatter mindst én opløselig, elektrokemisk art, der er i stand til at oxidere eller blive reduceret ved en elektrode i den elektrokemiske celle.
3. Fremgangsmåde ifølge krav 2, hvor den elektriske egenskab, der måles, er den elektrokemiske strøm ifølge amperometri.
4. Fremgangsmåde ifølge krav 2 eller krav 3, hvor de elektroaktive arter er salte af ferricyanid og ferrocyanid.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 4, hvor prøven er fuldblod eller plasma og ændringen i blodets eller plasmaets fysiske tilstand skyldes koagulation.
6. Fremgangsmåde ifølge krav 5, hvor den elektriske egenskab er den elektrokemisk strøm, hvor en algoritme er tilpasset til at identificere spidser i den elektrokemiske strøm, der er forårsaget af magnetisk partikelbevægelse og bestemme koagulationstiden for blod eller plasma.
7. Fremgangsmåde ifølge krav 6, hvor algoritmen beregner højden af spidser i strømme og definerer koagulationstiden baseret på, hvornår spidshøjden falder ned under en forhåndsbestemt tærskel.
8. Fremgangsmåde ifølge krav 6, hvor algoritmen bestemmer, om en spids i strøm er opstået inden for et forhåndsbestemt tidspunkt for ændring af magnetfeltet, og definerer koagulationstiden baseret på, om en sådan spids er under en forhåndsbestemt tærskel.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 8, hvor den elektrokemiske celle omfatter et bånd omfattende to elektroder.
10. Fremgangsmåde ifølge krav 9, hvor de to elektroder er parallelle med hinanden og adskilt med 0,05 til 0,5 mm, fortrinsvis 0,075 til 0,15 mm, og mest fortrinsvis 0,09 til 0,13 mm.
11. Fremgangsmåde ifølge krav 9, hvor de to elektroder er coplanare.
12. Fremgangsmåde ifølge krav 9, hvor de to elektroder er adskilt af et elektrisk isoleringslag, hvor laget har et hulrum, der er skåret i det til modtagelse af analytvæsken, såvel som en indgangsåbning til at tillade, at fluid trænger ind i hulrummet, og en udgangsåbning til den fortrængte luft.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 9 til 12, hvor prøven er fuldblod eller plasma og ændringen i blodets eller plasmaets fysiske tilstand skyldes koagulation, hvor prøven er deficient i forhold til koagulationsfaktorer, hvor båndet indeholder én eller flere koagulationsfaktorer, der kan erstatte de deficiente koagulationsfaktorer i prøven.
14. Anordning til elektrokemisk monitorering ifølge fremgangsmåden ifølge krav 1, hvilken anordning omfatter: en elektrokemisk celle omfattende et bånd, der omfatter to elektroder, magnetiske partikler, et fluidmodtagelsesområde, og et tilslutningsområde for et måleapparat; et middel til påføring af et eksternt felt, hvor det eksterne felt omfatter et ændrende eksternt magnetfelt; et middel til monitorering af en elektrisk egenskab for fluidet; og et middel til påvisning af en ændring i fluidets fysiske tilstand eller i partiklernes mobilitet ud fra en ændring i omfanget af den observerede elektriske egenskab.
15. Anordning ifølge krav 14, hvor midlet til monitorering af en elektrisk egenskab for fluidet omfatter et måleapparat omfattende en konnektor til elektrisk sammenkobling med elektroderne ved måleapparatets tilkoblingsområde for båndet og kredsløb til monitorering af den elektriske egenskab for fluidet, der er i kontakt med elektroderne.
16. Anordning ifølge krav 15, hvor midlet til påføring af et eksternt felt omfatter en magnet.
17. Anordning ifølge krav 16, hvor magneten er en elektromagnet.
18. Anordning ifølge et hvilket som helst af kravene 15 til 17, hvor måleapparatet omfatter et amperemeter.
19. Anordning ifølge et hvilket som helst af kravene 14 til 18, hvor de to eller flere elektroder er parallelle med hinanden eller coplanare.
20. Anordning ifølge et hvilket som helst af kravene 14 til 19, hvor båndet omfatter mindst ét reagens udvalgt fra gruppen bestående af en koagulationsfaktor, et koagulationsreagens og en elektroaktiv art.
21. Anordning ifølge krav 20, hvor koagulationsreagenset omfatter mindst ét reagens udvalgt fra gruppen bestående af et thromboplastin, en slangegift, en kontaktaktivator, et phospholipid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83124006P | 2006-07-17 | 2006-07-17 | |
| PCT/IB2007/001990 WO2008010058A1 (en) | 2006-07-17 | 2007-07-13 | Electrochemical detection of magnetic particle mobility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2047253T3 true DK2047253T3 (da) | 2016-02-15 |
Family
ID=38956592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07766626.1T DK2047253T3 (da) | 2006-07-17 | 2007-07-13 | Elektrokemisk påvisning af magnetisk partikelmobilitet |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8974658B2 (da) |
| EP (1) | EP2047253B1 (da) |
| JP (1) | JP5309024B2 (da) |
| KR (1) | KR101490531B1 (da) |
| CN (1) | CN101627305B (da) |
| AU (1) | AU2007274779B2 (da) |
| BR (1) | BRPI0714393A2 (da) |
| CA (1) | CA2659152C (da) |
| DK (1) | DK2047253T3 (da) |
| HU (1) | HUE028693T2 (da) |
| IL (1) | IL196555A (da) |
| MX (1) | MX2009000544A (da) |
| PL (1) | PL2047253T3 (da) |
| PT (1) | PT2047253E (da) |
| SG (1) | SG173379A1 (da) |
| SI (1) | SI2047253T1 (da) |
| TW (1) | TWI449906B (da) |
| WO (1) | WO2008010058A1 (da) |
| ZA (1) | ZA200900571B (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0812679D0 (en) | 2008-07-10 | 2008-08-20 | Sec Dep For Innovation Universities | Sample carrier for effecting chemical assays |
| GB0812681D0 (en) * | 2008-07-10 | 2008-08-20 | Sec Dep For Innovation Universities | Apparatus and methods for effecting chemical assays |
| TWI570408B (zh) * | 2009-04-17 | 2017-02-11 | 環球生物醫療感測器私人有限公司 | 電化學機載控制偵測 |
| GB201217390D0 (en) | 2012-09-28 | 2012-11-14 | Agplus Diagnostics Ltd | Test device and sample carrier |
| KR102252259B1 (ko) * | 2015-12-31 | 2021-05-14 | 주식회사 필로시스 | 혈액 응고 측정장치 |
| EP3415900B1 (en) * | 2016-02-10 | 2022-07-20 | Sony Group Corporation | Sample for measuring electrical characteristics, device for measuring electrical characteristics, and method for measuring electrical characteristics |
| CN108614017B (zh) * | 2016-12-09 | 2021-02-09 | 广州好芝生物科技有限公司 | 一种凝血酶原时间检测方法和装置 |
| WO2018115086A1 (en) * | 2016-12-22 | 2018-06-28 | Roche Diagnostics Gmbh | Determination of local mean normal prothrombin time and of local international sensitivity index |
| CN109827891A (zh) * | 2019-02-01 | 2019-05-31 | 天津中环领先材料技术有限公司 | 一种基于sp1颗粒测试仪的cop检测方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3522098A1 (de) | 1985-06-20 | 1987-01-02 | Jung Friedrich | Vorrichtung zur bestimmung einer der erythrozytenaggregation entsprechenden me?groesse |
| US5110727A (en) | 1987-04-03 | 1992-05-05 | Cardiovascular Diagnostics, Inc. | Method for performing coagulation assays accurately, rapidly and simply, using dry chemical reagents and paramagnetic particles |
| US4849340A (en) * | 1987-04-03 | 1989-07-18 | Cardiovascular Diagnostics, Inc. | Reaction system element and method for performing prothrombin time assay |
| FR2664981B1 (fr) * | 1990-07-20 | 1994-04-29 | Serbio | Dispositif de detection du changement de viscosite d'un electrolyte liquide par effet de depolarisation. |
| US5670329A (en) * | 1993-05-28 | 1997-09-23 | Cardiovascular Diagnostics, Inc. | Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field |
| FR2756501B1 (fr) * | 1996-11-29 | 1999-02-19 | Centre Nat Rech Scient | Procede et dispositif de separation de particules ou molecules par migration a travers un ferrofluide |
| WO1998049549A1 (en) * | 1997-04-30 | 1998-11-05 | Orion Research, Inc. | Capillary electrophoretic separation system |
| US6046051A (en) * | 1997-06-27 | 2000-04-04 | Hemosense, Inc. | Method and device for measuring blood coagulation or lysis by viscosity changes |
| EA002856B1 (ru) | 1997-07-22 | 2002-10-31 | Киото Дайити Кагаку Ко., Лтд. | Устройство для измерения концентрации, испытательная полоска для устройства для измерения концентрации, биосенсорная система и способ формирования контактных площадок на испытательной полоске |
| SE9800590D0 (sv) * | 1998-02-26 | 1998-02-26 | Global Hemostasis Inst Mgr Ab | Determination of polymerization/coagulation in a fluid |
| DE69839655D1 (de) * | 1998-07-29 | 2008-08-07 | Hemosense Inc | Verfahren und Gerät zur Messung der Blutkoagulation oder Lyse mit Hilfe von Viskositätsveränderungen |
| US6620310B1 (en) * | 2000-12-13 | 2003-09-16 | Lifescan, Inc. | Electrochemical coagulation assay and device |
| US7144495B2 (en) * | 2000-12-13 | 2006-12-05 | Lifescan, Inc. | Electrochemical test strip with an integrated micro-needle and associated methods |
| GB0030929D0 (en) * | 2000-12-19 | 2001-01-31 | Inverness Medical Ltd | Analyte measurement |
| KR100442822B1 (ko) * | 2001-10-23 | 2004-08-02 | 삼성전자주식회사 | 전단응력 측정을 이용한 생분자들간의 결합 여부 검출 방법 |
| US6746872B2 (en) * | 2002-01-16 | 2004-06-08 | Lifescan, Inc. | Control compositions and methods of use for coagulation tests |
| US7010432B2 (en) | 2002-08-30 | 2006-03-07 | Lifescan, Inc. | Method and system for determining the acceptability of signal data collected from a prothrombin time test strip |
| EP1544596B1 (de) * | 2003-12-17 | 2016-11-23 | Boehringer Ingelheim microParts GmbH | Verfahren und Vorrichtung zur Bestimmung der Viskosität |
| AU2005246084A1 (en) * | 2004-05-20 | 2005-12-01 | Inverness Medical Switzerland Gmbh | A device and method for detecting blood coagulation |
-
2007
- 2007-07-13 US US12/374,276 patent/US8974658B2/en active Active
- 2007-07-13 HU HUE07766626A patent/HUE028693T2/en unknown
- 2007-07-13 AU AU2007274779A patent/AU2007274779B2/en not_active Ceased
- 2007-07-13 CA CA2659152A patent/CA2659152C/en not_active Expired - Fee Related
- 2007-07-13 KR KR20097003086A patent/KR101490531B1/ko active Active
- 2007-07-13 EP EP07766626.1A patent/EP2047253B1/en not_active Not-in-force
- 2007-07-13 DK DK07766626.1T patent/DK2047253T3/da active
- 2007-07-13 PL PL07766626T patent/PL2047253T3/pl unknown
- 2007-07-13 SI SI200731740T patent/SI2047253T1/sl unknown
- 2007-07-13 BR BRPI0714393-1A patent/BRPI0714393A2/pt not_active Application Discontinuation
- 2007-07-13 WO PCT/IB2007/001990 patent/WO2008010058A1/en active Application Filing
- 2007-07-13 SG SG2011051497A patent/SG173379A1/en unknown
- 2007-07-13 CN CN200780028935.9A patent/CN101627305B/zh not_active Expired - Fee Related
- 2007-07-13 MX MX2009000544A patent/MX2009000544A/es active IP Right Grant
- 2007-07-13 JP JP2009520067A patent/JP5309024B2/ja not_active Expired - Fee Related
- 2007-07-13 PT PT77666261T patent/PT2047253E/pt unknown
- 2007-07-17 TW TW096126052A patent/TWI449906B/zh not_active IP Right Cessation
-
2009
- 2009-01-15 IL IL196555A patent/IL196555A/en active IP Right Grant
- 2009-01-26 ZA ZA200900571A patent/ZA200900571B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2047253T3 (pl) | 2016-06-30 |
| EP2047253A4 (en) | 2010-07-07 |
| SG173379A1 (en) | 2011-08-29 |
| BRPI0714393A2 (pt) | 2013-03-26 |
| SI2047253T1 (sl) | 2016-04-29 |
| IL196555A (en) | 2015-03-31 |
| EP2047253B1 (en) | 2015-11-04 |
| HUE028693T2 (en) | 2016-12-28 |
| IL196555A0 (en) | 2009-11-18 |
| EP2047253A1 (en) | 2009-04-15 |
| US8974658B2 (en) | 2015-03-10 |
| WO2008010058A1 (en) | 2008-01-24 |
| CN101627305A (zh) | 2010-01-13 |
| JP2009544031A (ja) | 2009-12-10 |
| US20090301901A1 (en) | 2009-12-10 |
| JP5309024B2 (ja) | 2013-10-09 |
| TWI449906B (zh) | 2014-08-21 |
| TW200806982A (en) | 2008-02-01 |
| KR101490531B1 (ko) | 2015-02-05 |
| CA2659152C (en) | 2015-11-03 |
| AU2007274779B2 (en) | 2013-05-09 |
| PT2047253E (pt) | 2016-03-11 |
| MX2009000544A (es) | 2009-05-28 |
| CN101627305B (zh) | 2015-03-04 |
| ZA200900571B (en) | 2009-11-25 |
| HK1128765A1 (zh) | 2009-11-06 |
| AU2007274779A1 (en) | 2008-01-24 |
| CA2659152A1 (en) | 2008-01-24 |
| KR20090033268A (ko) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2047253T3 (da) | Elektrokemisk påvisning af magnetisk partikelmobilitet | |
| US6338821B1 (en) | Method and device for measuring blood coagulation or lysis by viscosity changes | |
| EP1257801B1 (en) | System, method and computer implemented process for assaying coagulation in fluid samples | |
| AU2002239526B2 (en) | Electrochemical coagulation assay and device | |
| JP2016048248A (ja) | 電気化学検出のための装置および方法 | |
| EP1151268B1 (en) | Method and device for measuring blood coagulation or lysis by viscosity changes | |
| US20020187071A1 (en) | Method and device for clotting time assay | |
| Bisson et al. | A microanalytical device for the assessment of coagulation parameters in whole blood | |
| EP1482296B1 (en) | Method and device for measuring blood coagulating or lysis by viscosity changes | |
| HK1128765B (en) | Electrochemical detection of magnetic particle mobility | |
| Chang et al. | Determination of coagulation time in whole blood containing anticoagulant by piezoelectric quartz crystal sensor |